Derek Archila

Stock Analyst at Wells Fargo

(4.51)
# 482
Out of 5,182 analysts
235
Total ratings
56.88%
Success rate
19.49%
Average return

Stocks Rated by Derek Archila

Apellis Pharmaceuticals
Apr 17, 2026
Downgrades: Equal-Weight
Price Target: $26$41
Current: $40.95
Upside: +0.12%
Soleno Therapeutics
Apr 17, 2026
Downgrades: Equal-Weight
Price Target: $110$53
Current: $52.75
Upside: +0.47%
Nurix Therapeutics
Apr 9, 2026
Maintains: Overweight
Price Target: $29$28
Current: $16.49
Upside: +69.80%
Viridian Therapeutics
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $29$20
Current: $13.50
Upside: +48.15%
ALX Oncology Holdings
Mar 19, 2026
Initiates: Overweight
Price Target: $5
Current: $1.59
Upside: +214.47%
Monte Rosa Therapeutics
Mar 18, 2026
Maintains: Overweight
Price Target: $30$29
Current: $19.29
Upside: +50.34%
Rhythm Pharmaceuticals
Mar 12, 2026
Maintains: Overweight
Price Target: $136$143
Current: $85.20
Upside: +67.84%
Septerna
Mar 3, 2026
Maintains: Overweight
Price Target: $28$48
Current: $25.07
Upside: +91.50%
Disc Medicine
Mar 2, 2026
Maintains: Overweight
Price Target: $78$79
Current: $68.85
Upside: +14.74%
argenx SE
Feb 27, 2026
Maintains: Overweight
Price Target: $1,317$1,247
Current: $783.74
Upside: +59.11%
Maintains: Overweight
Price Target: $88$98
Current: $74.52
Upside: +31.51%
Maintains: Equal-Weight
Price Target: $107$101
Current: $95.72
Upside: +5.52%
Maintains: Overweight
Price Target: $322$330
Current: $226.66
Upside: +45.59%
Maintains: Equal-Weight
Price Target: $479$376
Current: $308.51
Upside: +21.88%
Maintains: Overweight
Price Target: $17$39
Current: $24.75
Upside: +57.58%
Maintains: Overweight
Price Target: $31$33
Current: $8.99
Upside: +267.07%
Maintains: Overweight
Price Target: $69$116
Current: $86.68
Upside: +33.83%
Maintains: Overweight
Price Target: $19$25
Current: $10.19
Upside: +145.34%
Maintains: Overweight
Price Target: $14$27
Current: $6.10
Upside: +342.62%
Maintains: Overweight
Price Target: $16$15
Current: $10.29
Upside: +45.77%
Maintains: Overweight
Price Target: $51$81
Current: $66.59
Upside: +21.64%
Maintains: Equal-Weight
Price Target: $36$30
Current: $44.65
Upside: -32.81%
Maintains: Equal-Weight
Price Target: $7$5
Current: $7.29
Upside: -31.41%
Maintains: Overweight
Price Target: $5$10
Current: $2.83
Upside: +253.36%
Downgrades: Equal-Weight
Price Target: $25$1
Current: $0.79
Upside: +26.44%
Maintains: Overweight
Price Target: $44$38
Current: $33.66
Upside: +12.89%
Maintains: Equal-Weight
Price Target: $40$30
Current: $33.59
Upside: -10.69%
Maintains: Equal-Weight
Price Target: $3$2
Current: $2.91
Upside: -31.27%
Maintains: Equal-Weight
Price Target: $6$5
Current: $4.25
Upside: +17.65%
Maintains: Equal-Weight
Price Target: $16$15
Current: $5.47
Upside: +174.22%
Maintains: Equal-Weight
Price Target: $12$14
Current: $28.56
Upside: -50.98%
Maintains: Overweight
Price Target: $47$45
Current: $28.62
Upside: +57.23%
Downgrades: Hold
Price Target: $37$20
Current: $1.91
Upside: +947.12%
Initiates: Buy
Price Target: $18
Current: $5.13
Upside: +250.88%
Downgrades: Hold
Price Target: $298$193
Current: $28.55
Upside: +576.01%
Reiterates: Buy
Price Target: $61$41
Current: $87.75
Upside: -53.28%
Maintains: Hold
Price Target: $480$160
Current: $13.93
Upside: +1,048.60%
Downgrades: Hold
Price Target: $180$60
Current: $20.39
Upside: +194.26%
Downgrades: Perform
Price Target: $29
Current: $6.79
Upside: +327.10%
Maintains: Outperform
Price Target: $34$50
Current: $1.19
Upside: +4,101.68%
Maintains: Outperform
Price Target: $32$51
Current: $23.77
Upside: +114.56%
Initiates: Outperform
Price Target: $88
Current: $11.49
Upside: +665.88%
Initiates: Market Perform
Price Target: n/a
Current: $25.55
Upside: -
Downgrades: Perform
Price Target: n/a
Current: $31.26
Upside: -